FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Hits Lupin with 5-item Form 483

[ Price : $8.95]

FDA issues Lupin a five-item Form 483 after an inspection at the firms Madhya Pradesh, India manufacturing plant cited significant...

FDA Clears NinePoint Real-time Image Segmentation

[ Price : $8.95]

FDA clears a NinePoint Medical 510(k) to market its Intelligent Real-time Image Segmentation software upgrade for its NvisionVLE I...

FDA Guide on Device UDI Compliance Dates

[ Price : $8.95]

Federal Register notice: FDA makes available a guidance entitled Unique Device Identification: Policy Regarding Compliance Dates f...

Info Collection Extension for Biosimilar User Fees

[ Price : $8.95]

Federal Register notice: FDA submits to OMB an information collection extension for Biosimilars User Fee Program.

Panel Backs Sage Postpartum Depression Drug

[ Price : $8.95]

A joint FDA panel meeting votes 17 to 1 that data support the benefit-risk profile of Sages Zulresso (brexanolone) injection for t...

510(k) for Shoulder Arthroplasty Cleared

[ Price : $8.95]

FDA clears a Shoulder Innovations 510(k) for the InSet Humeral Short Stem System for partial or total shoulder arthroplasty used i...

Safety Alert on Potential Label Problems with EpiPen

[ Price : $8.95]

FDA issues a safety alert about labels attached to some Pfizer/Mylan EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, which may b...

Latest Federal Register Notices

[ Price : $8.95]

FDA Review posts the Federal Register notices for the week ending 11/2/2018.

Draft Guide on New ANDA Review Letters

[ Price : $8.95]

FDA issues a draft guidance on Information Requests and Discipline Review Letters Under GDUFA that outlines how such letters will ...

FDA Revises Listing of Drugs Needing Generic Competition

[ Price : $8.95]

FDA improves transparency in a revised listing that identifies brand drugs that do not have any generic competition.